Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
678.3±55.0 °C at 760 mmHg
HS Code Reference
Personal Projective Equipment
For Reference Standard and R&D, Not for Human Use Directly.
provides coniferyl ferulate(CAS#:68401-05-8) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate
Controversy exists regarding adjuvant oxaliplatin treatment among older stage II and III colorectal cancer (CRC) patients. We sought to identify patient/tumor, physician, hospital, and geographic factors associated with oxaliplatin use among older patients.
Individuals diagnosed at age>65 with stage II/III CRC from 2004-2007 undergoing surgical resection and receiving adjuvant chemotherapy were identified using the Surveillance, Epidemiology and End Results program (SEER)-Medicare, a database including patient/tumor and hospital characteristics. Physician information was obtained from the American Medical Association. We used Poisson regression to identify independent predictors of oxaliplatin receipt. The discriminatory ability of each category of characteristics to predict oxaliplatin receipt was assessed by comparing the area under the receiver operating curve (AUC) from logistic regression models.
We identified 4,388 individuals who underwent surgical resection at 773 hospitals and received chemotherapy from 1,517 physicians. Adjuvant oxaliplatin use was higher among stage III (colon=56%, rectum=51%) compared to stage II patients (colon=37%, rectum=35%). Overall, patients who were older, diagnosed before 2006, separated, divorced or widowed, living in a higher poverty census tract or in the East or Midwest, or with higher levels of comorbidity were less likely to receive oxaliplatin. Patient factors and calendar year accounted for most of the variation in oxaliplatin receipt (AUC=75.8%).
Adjuvant oxaliplatin use increased rapidly from 2004-2007 despite uncertainties regarding its effectiveness in older patients. Physician and hospital characteristics had little influence on adjuvant oxaliplatin receipt among older patients.
colorectal cancer, chemotherapy, SEER Program, Medicare
DETERMINANTS OF ADJUVANT OXALIPLATIN RECEIPT AMONG OLDER STAGE II AND III COLORECTAL CANCER PATIENTS
Jennifer L Lund, PhD,1,2 Til Sturmer, MD, PhD,1 Hanna K Sanoff, MD, MPH,3 Alan Brookhart, PhD,1 Robert S Sandler, MD, MPH,3 and Joan L Warren, PhD4
2014 Jun 1.
Brassinosteroid hormones regulate many aspects of plant growth and development. The membrane receptor BRI1 is a central player in the brassinosteroid signaling cascade. Semi-dwarf ‘uzu’ barley carries a mutation in a conserved domain of the kinase tail of BRI1 and this mutant allele is recognised for its positive contribution to both yield and lodging resistance.
Here we show that uzu barley exhibits enhanced resistance to a range of pathogens. It was due to a combination of preformed, inducible and constitutive defence responses, as determined by a combination of transcriptomic and biochemical studies. Gene expression studies were used to determine that the uzu derivatives are attenuated in downstream brassinosteroid signaling. The reduction of BRI1 RNA levels via virus-induced gene silencing compromised uzu disease resistance.
The pathogen resistance of uzu derivatives may be due to pleiotropic effects of BRI1 or the cascade effects of their repressed BR signaling.
Electronic supplementary material
The online version of this article (doi:10.1186/s12870-014-0227-1) contains supplementary material, which is available to authorized users.
Disease resistance, Brassinosteroid, Uzu, BRI1, Fusarium
Plant disease resistance is augmented in uzu barley lines modified in the brassinosteroid receptor BRI1
Shahin S Ali,corresponding author Lokanadha R Gunupuru, G B Sunil Kumar, Mojibur Khan, Steve Scofield, Paul Nicholson, and Fiona M Doohan
This study aimed to assess the efficacy of canal filling material removal using three different techniques after filling with a Gutta-Percha (GP) cone and calcium silicate-based sealer, by measuring the percentage of volume debris of GP and sealer remaining intracanal with micro computed tomography (micro-CT). The filling material was removed from 30 plastic teeth by a nickel-titanium (Ni-Ti) rotary retreatment system. Final irrigation was performed with 2 mL of saline and 10 specimens were randomly allocated to a conventional group. In the passive ultrasonic irrigation (PUI) group, ultrasonic irrigation was added to the conventional group (n = 10). In the Gentlefile Brush (GF Brush) group, irrigation with GF Brush was added to the conventional group (n = 10). Remaining filling material was measured using micro-CT imaging analysis. The total mean volume of residual filling material after retreatment in the conventional group, PUI group and GF Brush group were 4.84896 mm3, 0.80702 mm3, and 0.05248 mm3, respectively. The percentage of filling material remaining intracanal was 6.76% in the conventional group, 1.12% in the PUI group and 0.07% in the GF Brush group. This study shows that the cleaning effect of the GF Brush system is superior to those of Ni-Ti retreatment files and the PUI system in the apical area.
endodontic retreatment, root canal retreatment, Gentlefile Brush, passive ultrasonic irrigation, micro-CT
Comparison of the Efficacy of Different Techniques for the Removal of Root Canal Filling Material in Artificial Teeth: A Micro-Computed Tomography Study
Tuan Anh Nguyen,1,† Yaelim Kim,1,† Euiseong Kim,1,2 Su-Jung Shin,3 and Sunil Kim1,*